Why Amarin Stock Imploded in March
Amarin (NASDAQ: AMRN) lost a staggering 72.7% of its value in March, according to data from S&P Global Market Intelligence. The drugmaker's shares collapsed late in the month following an adverse patent ruling for its prescription omega-3 treatment, Vascepa.
This somewhat surprising patent decision by the U.S. District Court for the District of Nevada paves the way for generics to enter the all-important U.S. market. The company said it will file an immediate injunction to block the launch of a generic upon approval. Amarin also plans on appealing the decision.
Image source: Getty Images.
Source Fool.com
